# Study of How Safe and Effective Tarlatamab is in Brain Cancers

> **NCT06776250** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 44 (estimated)

## Conditions studied

- Astrocytic Tumor
- Oligodendroglial Tumor

## Interventions

- **DRUG:** Tarlatamab

## Key facts

- **NCT ID:** NCT06776250
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2028-03-03
- **Final completion:** 2028-03-03
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06776250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06776250, "Study of How Safe and Effective Tarlatamab is in Brain Cancers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06776250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*